Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Therapeutics Initiates Infectious Disease Programs\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Second Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Final Tranche of Fully Subscribed Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Reports Excellent Rotigotine In-Vitro\/Ex-Vivo Results for Parkinson's Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by XPhyto

    Menu

    XPhyto

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              XPhyto

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment

              Details:

              Rotigotine is non-ergoline dopamine agonist approved for treatment of Parkinson’s disease and restless legs syndrome.Active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability.

              Lead Product(s): Rotigotine

              Therapeutic Area: Neurology Product Name: ROV045

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              XPhyto

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              XPhyto Closes Final Tranche of Fully Subscribed Financing

              Details:

              The company will use net proceeds of the financing to fund its research, development and commercialization activities for its lead Rotigotine and other pipeline candidates and for general working capital.

              Lead Product(s): Rotigotine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $3.6 million Upfront Cash: Undisclosed

              Deal Type: Financing September 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              XPhyto

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              XPhyto Closes Second Tranche of Financing

              Details:

              The Company will use net proceeds of the placement to fund its research, development and commercialization activities especially for it's lead rotigotine and for general working capital.

              Lead Product(s): Rotigotine

              Therapeutic Area: Neurology Product Name: ROV045

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $1.8 million Upfront Cash: Undisclosed

              Deal Type: Private Placement August 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              XPhyto

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              XPhyto Therapeutics Initiates Infectious Disease Programs

              Details:

              The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.

              Lead Product(s): Cannabigerol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY